Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011, Article ID 628084, 6 pages
http://dx.doi.org/10.1155/2011/628084
Research Article

Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression

1Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208063, New Haven, CT 06520, USA
2Department of Pathology, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06520, USA
3Yale School of Public Health, Yale University, 60 College Street, New Haven, CT 06520, USA

Received 5 August 2011; Revised 11 October 2011; Accepted 15 October 2011

Academic Editor: Richard T. Penson

Copyright © 2011 Joyce Varughese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. Mendivil, K. M. Schuler, and P. A. Gehrig, “Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes,” Cancer Control, vol. 16, no. 1, pp. 46–52, 2009. View at Google Scholar · View at Scopus
  3. A. Gadducci, S. Cosio, N. Spirito, and L. Cionini, “Clear cell carcinoma of the endometrium: a biological and clinical enigma,” Anticancer Research, vol. 30, no. 4, pp. 1327–1334, 2010. View at Google Scholar · View at Scopus
  4. A. B. Olawaiye and D. M. Boruta, “Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review,” Gynecologic Oncology, vol. 113, no. 2, pp. 277–283, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. T. P. Boren and D. S. Miller, “Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?” Women's Health, vol. 6, no. 6, pp. 789–795, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. W. T. Creasman, M. F. Kohler, F. Odicino, P. Maisonneuve, and P. Boyle, “Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium,” Gynecologic Oncology, vol. 95, no. 3, pp. 593–596, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Thomas, A. Mariani, J. D. Wright et al., “Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review,” Gynecologic Oncology, vol. 108, no. 2, pp. 293–297, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. K. K. Zorn, T. Bonome, L. Gangi et al., “Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer,” Clinical Cancer Research, vol. 11, no. 18, pp. 6422–6430, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. I. Risinger, G. L. Maxwell, G. V. R. Chandramouli et al., “Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer,” Cancer Research, vol. 63, no. 1, pp. 6–11, 2003. View at Google Scholar · View at Scopus
  10. V. M. Abeler and K. E. Kjorstad, “Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases,” Gynecologic Oncology, vol. 40, no. 3, pp. 207–217, 1991. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Vandenput, T. Vanhove, B. V. Calster et al., “The use of lymph vessel markers to predict endometrial cancer outcome,” International Journal of Gynecological Cancer, vol. 20, no. 3, pp. 363–367, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. A. Rauh-Hain, W. B. Growdon, J. O. Schorge et al., “Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma,” Gynecologic Oncology, vol. 119, no. 2, pp. 299–304, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. D. S. McMeekin, V. L. Filiaci, J. T. Thigpen, H. H. Gallion, G. F. Fleming, and W. H. Rodgers, “The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 106, no. 1, pp. 16–22, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. A. Sovak, M. L. Hensley, J. Dupont et al., “Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study,” Gynecologic Oncology, vol. 103, no. 2, pp. 451–457, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. Pignata, G. Scambia, C. Pisano et al., “A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group,” British Journal of Cancer, vol. 96, no. 11, pp. 1639–1643, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. S. Kwon, J. Abrams, A. Sugimoto, and M. S. Carey, “Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?” International Journal of Gynecological Cancer, vol. 18, no. 4, pp. 820–824, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. R. Curtis, E. Ron, B. Hankey, and B. Hoover, “New malignancies following breast cancer,” in New Malignancies Among Cancer Survivors: SEER Cancer Registries 1973–2000, R. E. Curtis, D. M. Freedman, E. Ron et al., Eds., pp. 181–205, National Cancer Institute, Bethesda, Md, USA, 2006. View at Google Scholar
  18. S. X. Liang, M. Pearl, S. Liang et al., “Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger,” International Journal of Cancer, vol. 128, no. 4, pp. 763–770, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. L. Carcangiu, P. Radice, P. Casalini, L. Bertario, M. Merola, and P. Sala, “Lynch syndrome-related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types,” International Journal of Surgical Pathology, vol. 18, no. 1, pp. 21–26, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. K. H. Lu, M. Dinh, W. Kohlmann et al., “Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome,” Obstetrics & Gynecology, vol. 105, no. 3, pp. 569–574, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. G. Kelly, D. M. O'Malley, P. Hui et al., “Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy,” Gynecologic Oncology, vol. 98, no. 3, pp. 353–359, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus